Cytek Biosciences (CTKB) Acquisitions (2023 - 2024)

Cytek Biosciences' (CTKB) quarterly Acquisitions came in at $471000.0 in Q4 2024, up 47000.0% on a QoQ basis from $1000.0 in Q3 2023.

Cytek Biosciences (CTKB) Acquisitions (2023 - 2024) Analysis & Trends

Cytek Biosciences (CTKB) has 2 years of Acquisitions data on file, last reported at $471000.0 in Q4 2024.

Quarterly Acquisitions changed N/A year-over-year to $471000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $471000.0 (down 98.95% YoY) and the FY2024 annual result came in at $471000.0, down 98.95% from the prior year.
Acquisitions improved to $471000.0 in Q4 2024, from $1000.0 in the prior quarter.
In the past five years, Acquisitions ranged from a high of $44.9 million in Q1 2023 to a low of $1000.0 in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Acquisitions (Qtr)
1	Abbott Laboratories	199.12 Bn	193.52 Bn	7.27 Bn	-
2	Stryker	128.79 Bn	125.32 Bn	4.50 Bn	437.00 Mn
3	Medtronic	119.30 Bn	110.08 Bn	6.41 Bn	406.00 Mn
4	Boston Scientific	73.50 Bn	72.96 Bn	3.85 Bn	-
5	Edwards Lifesciences	52.11 Bn	47.86 Bn	1.35 Bn	-
6	Dexcom	34.62 Bn	32.67 Bn	830.00 Mn	-
7	GE HealthCare Technologies	34.05 Bn	31.94 Bn	2.18 Bn	-4.00 Mn
8	Koninklijke Philips	26.42 Bn	23.10 Bn	4.55 Bn	-3.49 Mn
9	Steris	23.15 Bn	22.67 Bn	684.20 Mn	16.00 Mn
10	Cytek Biosciences	612.35 Mn	538.50 Mn	28.34 Mn	-

Download Data